Loading...
Docoh

Humanigen (HGEN)

Humanigen, Inc. is developing its portfolio of Humaneered® monoclonal antibodies to address cutting-edge CAR-T optimization and oncology treatments advancing safer, better, and more effective cancer therapies. Derived from the company's Humaneered® platform, lenzilumab and ifabotuzumab are monoclonal antibodies with first-in-class mechanisms. Lenzilumab, which targets GM-CSF, is in development as a potential biologic therapy to make CAR-T therapy safer and more effective, as well as a potential treatment for rare hematologic cancers such as CMML and JMML. Ifabotuzumab, which targets the Eph type-A receptor 3 (EphA3), is being explored as a potential treatment for glioblastoma multiforme (GBM) and other deadly cancers, both as naked antibody and as part of an antibody-drug conjugate, as well as a backbone for a novel CAR-T construct, and a bispecific antibody platform.

Company profile

Ticker
HGEN
Exchange
CEO
Cameron Durrant
Employees
Incorporated
Location
Fiscal year end
Former names
KALOBIOS PHARMACEUTICALS INC
SEC CIK
Subsidiaries
Humanigen, Ltd. • Humanigen Australia • Humanigen Europe, Ltd. ...
IRS number
770557236

HGEN stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
$2.00
Low target
$2.00
High target
$2.00
Roth Capital
Downgraded
Neutral
$2.00
13 Jul 22
Cantor Fitzgerald
Downgraded
Neutral
$2.00
13 Jul 22

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

12 Aug 22
1 Oct 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 47.05M 47.05M 47.05M 47.05M 47.05M 47.05M
Cash burn (monthly) 7.3M 6.12M 9.78M 12.35M 8.46M 10.42M
Cash used (since last report) 22.39M 18.79M 30.01M 37.88M 25.95M 31.97M
Cash remaining 24.65M 28.26M 17.03M 9.16M 21.1M 15.07M
Runway (months of cash) 3.4 4.6 1.7 0.7 2.5 1.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
27 Jul 22 Buxton Cheryl Stock Option Common Stock Grant Acquire A No No 0.38 78,362 29.78K 78,362
27 Jul 22 John Hohneker Stock Option Common Stock Grant Acquire A No No 0.38 63,195 24.01K 63,195
27 Jul 22 Barliant Ronald Stock Option Common Stock Grant Acquire A No No 0.38 55,612 21.13K 55,612
27 Jul 22 Adrian Kilcoyne Stock Option Common Stock Grant Acquire A No No 0.38 537,164 204.12K 537,164
27 Jul 22 Chappell Dale Stock Option Common Stock Grant Acquire A No No 0.38 518,205 196.92K 518,205
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change

Financial report summary

?
Management Discussion
  • At June 30, 2022, we had an accumulated deficit of $662.5 million. Since inception, we have recognized a nominal amount of revenue from payments for license or collaboration fees. Our product candidates may never be successfully developed or commercialized and we may therefore never realize revenue from any product sales. Accordingly, we expect to continue to incur substantial losses from operations for the foreseeable future, and there can be no assurance that we will ever generate significant revenue or profits. Our ability to continue as a going concern depends on our ability to attain a significant amount of additional financing, as more fully described below under “—Liquidity and Capital Resources” and in “Risk Factors” in Item 1A of Part II below.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: alive, AML, azacitidine, blood, bore, Catalent, CBL, Clonal, commonly, comprehensive, cure, cytogenic, deemphasize, deployment, destroyed, destruction, DNA, Emanuel, enrichment, envisioned, expiry, extinguishing, extrapolated, Fisher, flow, genetic, Gupta, healthy, hyperresponsive, hypersensitivity, IIT, incidence, JMML, juvenile, leukaemia, leukemic, MDS, mentioned, MSA, multinational, myelodysplastic, myeloid, myeloproliferative, Orange, overproduction, Padron, people, Pharma, pharmacokinetic, PK, prepaid, principle, proof, proportion, rare, RAS, realigned, realignment, reconsidering, renegotiate, retiring, Retrieved, settle, shelf, SHIELD, shifted, Society, sponsorship, stored, Thermo, tolerability, traditionally, Unfair, unjust, Victorian, volunteer, waiver
Removed: abandon, accurately, advance, age, allege, alleged, Alliance, altogether, application, approve, bear, begin, beginning, BLA, borrowed, breached, broadly, caption, captioned, chemistry, CMO, commenced, committed, complaint, comprise, conditioned, confirm, contemplated, convert, cooperate, coupled, decision, deemed, defendant, deliver, derive, determine, disclose, distribution, Dr, duration, Durrant, dysfunction, elevated, equitable, EU, event, evolution, expand, expertise, expressly, extension, FDA, focused, Food, forecast, generated, governmental, greatest, inability, Index, individual, influence, insolvency, introduced, knockout, label, limit, limitation, lung, manufactured, maturity, mutual, newly, Noble, obtaining, occurred, offered, orderly, organ, pandemic, partner, placement, prejudice, prepare, present, preventing, prospective, protein, purpose, qualification, ranging, raw, recover, renew, repay, resulted, resulting, return, separate, service, source, state, strength, Supreme, syndrome, thousand, transitioned, treat, type, unfavorable, Union, utilizing, wind, York

Patents

Utility
Materials and Methods for Treating Cancer
10 Feb 22
This document provides methods and materials involved in treating cancer.
Utility
Methods of Treating Immunotherapy-related Toxicity Using a GM-CSF Antagonist
27 Jan 22
Methods for reducing blood-brain barrier disruption in a subject treated with immunotherapy, the method comprising administering a recombinant GM-CSF antagonist to the subject.
Utility
Methods of Treating Immunotherapy-related Toxicity Using a GM-CSF Antagonist
21 Oct 21
Methods for neutralizing and/or removing human GM-CSF in a subject in need thereof, comprising administering to the subject CAR-T cells having a GM-CSF gene knockout (GM-CSFk/o CAR-T cells) are provided.
Utility
Methods for Treating Coronavirus Infection and Resulting Inflammation-induced Lung Injury
7 Oct 21
The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.
Utility
Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
28 Sep 21
Methods for reducing blood-brain barrier disruption in a subject treated with immunotherapy, the method comprising administering a recombinant GM-CSF antagonist to the subject.